01 January 2002
Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma - a double-blind randomized placebo-controlled multicentre clinical trial
Marc F Goldstein, Paul ChervinskyMed Sci Monit 2002; 8(4): CR297-304 :: ID: 420864
Abstract
BACKGROUND: Experimental studies have shown that doxofylline is endowedwith a remarkable bronchodilator activity with less extra-respiratory effects than theophylline. Thistrial was designed to compare the efficacy and safety of doxofylline, theophylline, and placebo in patientswith chronic reversible bronchial asthma. MATERIAL/METHODS: Three hundred forty-six patients were randomlyassigned to a 12-week oral treatment with either doxofylline 400 mg t.i.d. (high dose), doxofylline 200mg t.i.d. (low dose), theophylline 250 mg t.i.d. (active control) or placebo. Pulmonary function tests(PFTs) were performed biweekly. Patients kept records of peak flow meter (PFM) measurements, asthma attackrate and beta-2-agonist use (albuterol). RESULTS: Changes in FEV1 2 hours after the administration oftreatments versus baseline exhibited statistically significant differences between doxofylline 400 mgt.i.d. and placebo and between theophylline and placebo. Similar differences were monitored on the othervariables (FVC, PFER, FEF(25-75%). Asthma attack rate and use of albuterol decreased remarkably withdoxofylline 400 mg t.i.d. and theophylline. There were few statistically significant differences betweendoxofylline 200 mg t.i.d. and placebo. Significantly more patients had to interrupt treatment becauseof adverse events under theophylline than under doxofylline 400 mg t.i.d. (p=0.001). With doxofylline400 mg t.i.d., the number of patients treated to spare one drop-out due to theophylline was 5. CONCLUSIONS:This study provides evidence that doxofylline 400 mg t.i.d. is an effective treatment for relieving airwayobstruction and displays a better safety profile with respect to theophylline 250 mg t.i.d. with a favorablerisk-to-benefit ratio.
Keywords: Adrenergic beta-Agonists, Albuterol, Anti-Asthmatic Agents, Asthma, Comparative Study, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Forced Expiratory Volume, Gastrointestinal Diseases, Headache, Placebos, Respiratory Function Tests, Safety, Single-Blind Method, Tachycardia, Theophylline
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
26 Feb 2024 : Clinical Research
Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in...Med Sci Monit In Press; DOI: 10.12659/MSM.942509
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952